Related Experiment Video
Updated: May 8, 2026
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Fecal transplant for recurrent Clostridium difficile infection
Denene Lofland1, Floyd Josephat, Sarah Partin
1Atlantic State University, Department of Medical Laboratory Science, Savannah, GA 31419, USA. Denene.lofland@armstrong.edu
Summary
Clostridium difficile infection (CDI) is a serious condition often caused by antibiotics. Fecal microbiota transplant (FMT) shows promise as an effective treatment for recurrent CDI cases.
Area of Science:
- Gastroenterology and Infectious Diseases
- Microbiology
- Clinical Medicine
Background:
- Clostridium difficile infection (CDI) presents with varied severity, from mild diarrhea to severe pseudomembranous colitis.
- Antimicrobial therapy disrupts colonic microflora, often initiating CDI.
- The C. difficile toxins A and B are key factors in damaging the intestinal lining.
Observation:
- Recent years have seen a rise in CDI rates, mortality, and recurrence.
- Treatment resistance and prolonged recovery times are increasing concerns.
- Traditional antimicrobial treatments are often insufficient for severe or recurrent cases.
Findings:
- Fecal microbiota transplant (FMT) is emerging as a highly effective alternative therapy for patients with recurrent CDI.
- FMT re-establishes a balanced gut microbiome, counteracting the effects of C. difficile.
- This overview covers CDI epidemiology, pathogenesis, diagnosis, and treatment, including a case study.
Implications:
- FMT offers a promising therapeutic strategy for managing difficult-to-treat CDI.
- Understanding CDI pathogenesis is crucial for developing targeted interventions.
- Further research into microbiome restoration is vital for combating infectious diseases.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...